The Effect of Zopiclone Co-administration on Sertraline Initial Dosage Optimization in Pediatric Major Depressive Disorder Patients Based on Model-informed Precision Dosing

Overview

Journal Front Pharmacol

Date 2025 Jan 22

PMID 39840087

Authors

Xiao Chen

Ke Hu

Hao-Zhe Shi

Su-Mei He

Yang Yang

Chao-Wen Yang

Yue Zhang

Xue Tian

Ye Li

Yu-Hang Gao

Wen-Yi Xu

Cun Zhang

Dong-Dong Wang

Affiliations

Soon will be listed here.

Abstract

Objective: The present study aims to explore the initial dosage optimization of sertraline in pediatric major depressive disorder (MDD) patients based on model-informed precision dosing (MIPD).

Methods: A total of 111 pediatric MDD patients treated with sertraline were included for analysis using MIPD. Sertraline concentration levels, physiological and biochemical indexes of pediatric MDD patients, combined drug information were included in the construction of model.

Results: Weight and zopiclone co-administration influenced sertraline clearance in pediatric MDD patients. With the same weight, the sertraline clearance rates were 0.453:1 in patients with, or without zopiclone, respectively. Furthermore, without zopiclone, for once-daily sertraline scheme, the dosages of 4.0, and 3.0 mg/kg/day were suggested for pediatric MDD patients with body weight of 30-38.5, and 38.5-80 kg, respectively; for twice-daily sertraline scheme, the dosage of 2.0 mg/kg/day was suggested for pediatric MDD patients with body weight of 30-80 kg. With zopiclone, for once-daily sertraline scheme, the dosage of 1.0 mg/kg/day was suggested for pediatric MDD patients with body weight of 30-80 kg; for twice-daily sertraline scheme, the dosage of 0.5 mg/kg/day was suggested for pediatric MDD patients with body weight of 30-80 kg.

Conclusion: This study first explored the initial dosage optimization of sertraline in pediatric MDD patients based on MIPD, and recommended the optimal sertraline initial dosage in pediatric MDD patients based on zopiclone co-administration.

References

Devane C, Liston H, Markowitz J . Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002; 41(15):1247-66. DOI: 10.2165/00003088-200241150-00002. View

Konecki C, Lesaffre F, Guillou S, Feliu C, Dubuisson F, Labdaoui M . Population pharmacokinetics of unfractionated heparin and multivariable analysis of activated clotting time in patients undergoing radiofrequency ablation of atrial fibrillation. Biomed Pharmacother. 2024; 181:117700. DOI: 10.1016/j.biopha.2024.117700. View

Obach R, Cox L, Tremaine L . Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2004; 33(2):262-70. DOI: 10.1124/dmd.104.002428. View

Anderson B, Holford N . Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2007; 48:303-32. DOI: 10.1146/annurev.pharmtox.48.113006.094708. View

Zheng Y, Xu B, Chen S, Liu M, Huang H, Wang J . Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients. J Clin Pharmacol. 2023; 63(9):1036-1044. DOI: 10.1002/jcph.2261. View

Kristensen J, Ilett K, Dusci L, Hackett L, Yapp P, Roberts M . Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol. 1998; 45(5):453-7. PMC: 1873544. DOI: 10.1046/j.1365-2125.1998.00705.x. View

Park R, Goodyer I . Clinical guidelines for depressive disorders in childhood and adolescence. Eur Child Adolesc Psychiatry. 2000; 9(3):147-61. DOI: 10.1007/s007870070038. View

Hao G, Huang X, Zhang D, Zheng Y, Shi H, Li Y . Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. Br J Clin Pharmacol. 2018; 84(8):1748-1756. PMC: 6046506. DOI: 10.1111/bcp.13605. View

Mathers C, Loncar D . Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11):e442. PMC: 1664601. DOI: 10.1371/journal.pmed.0030442. View

10.

Hu K, Fu M, Huang X, He S, Jiao Z, Wang D . Editorial: Model-informed drug development and precision dosing in clinical pharmacology practice. Front Pharmacol. 2023; 14:1224980. PMC: 10348903. DOI: 10.3389/fphar.2023.1224980. View

11.

Liu J, Yang L, Zheng Y, Kang C, Wang X, Shi J . Rural-urban differences in prevalence and correlates of suicidal ideation in adolescent patients with depression in a large sample of Chinese. J Affect Disord. 2022; 322:118-124. DOI: 10.1016/j.jad.2022.11.032. View

12.

Smith K . Mental health: a world of depression. Nature. 2014; 515(7526):181. DOI: 10.1038/515180a. View

13.

Poweleit E, Taylor Z, Mizuno T, Vaughn S, Desta Z, Strawn J . Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients. Clin Pharmacokinet. 2023; 62(11):1621-1637. PMC: 11003701. DOI: 10.1007/s40262-023-01294-8. View

14.

Xie H, Zheng Y, Wang C, Song S, Dai Y, Huang X . Managing delayed or missed pregabalin doses in patients with focal epilepsy: a Monte Carlo simulation study. Int J Clin Pharm. 2023; 46(1):150-157. DOI: 10.1007/s11096-023-01657-y. View

15.

Perez L, Corne P, Pasquier G, Konecki C, Sadek M, Le Bihan C . Population Pharmacokinetics of Isavuconazole in Critical Care Patients with COVID-19-Associated Pulmonary Aspergillosis and Monte Carlo Simulations of High Off-Label Doses. J Fungi (Basel). 2023; 9(2). PMC: 9960864. DOI: 10.3390/jof9020211. View

16.

Tsai M, Wang W, Roan J, Luo C, Chou C . Population Pharmacokinetics of Vancomycin in Intensive Care Patients with the Time-Varying Status of Temporary Mechanical Circulatory Support or Continuous Renal Replacement Therapy. Infect Dis Ther. 2024; 13(12):2617-2635. PMC: 11582109. DOI: 10.1007/s40121-024-01071-5. View

17.

Li C, Pollock B, Lyketsos C, Vaidya V, Drye L, Kirshner M . Population pharmacokinetic modeling of sertraline treatment in patients with Alzheimer disease: the DIADS-2 study. J Clin Pharmacol. 2013; 53(2):234-9. PMC: 3604147. DOI: 10.1177/0091270012445793. View

18.

Zhang Z, Guo Z, Tan Y, Li L, Wang Z, Wen Y . Population pharmacokinetic approach to guide personalized sertraline treatment in Chinese patients. Heliyon. 2024; 10(3):e25231. PMC: 10861969. DOI: 10.1016/j.heliyon.2024.e25231. View

19.

Alderman J, Wolkow R, Chung M, Johnston H . Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry. 1998; 37(4):386-94. DOI: 10.1097/00004583-199804000-00016. View

20.

Alhadab A, Brundage R . Population Pharmacokinetics of Sertraline in Healthy Subjects: a Model-Based Meta-analysis. AAPS J. 2020; 22(4):73. DOI: 10.1208/s12248-020-00455-y. View